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Abstract
Objective: Previous prospective studies on the association between vitamin D status and depression used a single 
25-hydroxyvitamin D (25(OH)D) measurement. We investigated the association between change in serum 25(OH)D and 
parallel change in depressive symptoms over time in Dutch older adults.
Design: A population-based, prospective study in two cohorts of older men and women from the Longitudinal Aging 
Study Amsterdam.
Methods: Serum 25(OH)D concentrations were determined at two time points: in 1995/1996 and 13 years later in the 
older cohort (aged 65–88y, n = 173) and in 2002/2003 and 6 years later in the younger cohort (55–65 years, n = 450). At 
these time points, depressive symptoms were measured with the Center for Epidemiologic Studies Depression scale 
(CES-D). Associations were tested by multiple linear regression analyses.
Results: During follow-up, serum 25(OH)D concentrations increased in 32.4% of the older cohort and in 69.8% of the 
younger cohort. In the older cohort, change in 25(OH)D was not associated with change in CES-D score. In the younger 
cohort, no associations were observed in participants with higher baseline 25(OH)D concentrations (>58.6 nmol/L), but 
in those with lower baseline 25(OH)D concentrations, an increase in 25(OH)D was associated with a decrease in CES-D 
score (adjusted B per 10 nmol/L 25(OH)D increase: −0.62 (95% CI: −1.17, −0.07)).
Conclusions: Our study suggests that over 6 years, an increase in serum 25(OH)D is associated with a small decrease 
in depressive symptoms in young older adults with lower baseline 25(OH)D. Well-designed intervention trials are 
required to determine causality.
Introduction
Depression is a major cause of disability and common 
in older adults (1, 2). Clinically relevant depressive 
symptoms affect 8 to 16% of the community-dwelling 
older population, and prevalence estimates of major 
depression in this population range from 1 to 4% (3). 
Depression has adverse health consequences, such as 
disability, cardiovascular disease, diabetes and premature 
death, as well as social and economic consequences (4). 
However, the aetiology of late-life depression is poorly 
understood.
Several pathways are involved in the aetiology of late-
life depression. Vitamin D, a neurosteroid hormone, may 
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play a role in the development of depression, as vitamin D 
receptors and the activating enzyme 1-α-hydroxylase are 
present in areas of the human brain that are related to 
mood (5, 6). In addition, the active metabolite of vitamin D, 
1,25-dihydroxyvitamin D, influences the synthesis of 
monoamine neurotransmitters such as serotonin. This 
metabolite also affects the regulation of neurotrophic 
factors and stimulates anti-inflammatory actions in 
the brain (6, 7, 8). Low serum 25-hydroxyvitamin D 
(25(OH)D) concentrations are highly prevalent in older 
adults, as a result of reduced exposure to sunlight, a 
decreased efficiency of the skin to synthesise vitamin D3 
and lower dietary intake (9).
Previous research has suggested an association 
between vitamin D status and depression. In many cross-
sectional studies, lower 25(OH)D concentrations were 
associated with a higher risk of depressive symptoms 
or depression (e.g. (10, 11)), while in others, vitamin D 
and depression were not associated (12, 13). Prospective 
studies showed a higher incidence of depressive 
symptoms or depression over 1–6 years in older persons 
who had low baseline vitamin D levels (14, 15, 16, 17, 
18). However, no prospective associations were found 
over 4–15  years in older adults (19, 20), older men 
(21, 22) and adults (23). Similarly, we recently found no 
cross-sectional and prospective associations of serum 
25(OH)D concentrations with depressive symptoms in 
Dutch older men and women, except for a higher risk of 
depressive symptoms over 6 years in older women with 
baseline 25(OH)D concentrations below 75 nmol/L (24). 
Differences in measures of vitamin D status and depression, 
study populations, analysis techniques, covariates and 
latitude may have given rise to these inconsistencies. 
Furthermore, experimental studies have found inconsistent 
results as well (e.g. (25, 26)). Meta-analyses of randomised 
controlled trials (RCTs) did not find support for the efficacy 
of vitamin D supplementation in depression; however, 
heterogeneity between the included trials was high 
(27, 28, 29, 30). A recent review on observational studies 
and RCTs has indicated that vitamin D deficiency may be 
a risk factor for late-life depression based on observational 
data but not on experimental data (31).
Previous research thus shows that the potential causal 
role of vitamin D status in depression risk is currently 
not clear. Next to well-designed RCTs, prospective 
studies are of interest to gain a better insight into 
this association in the general population. One of the 
limitations of all previous prospective studies is that 
only a single measurement of serum 25(OH)D was used 
(14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24). Vitamin 
D levels vary due to changes in sunlight exposure, 
diet and supplement use (32, 33); therefore, multiple 
intra-individual measurements are needed for a better 
understanding of the longitudinal association. To date, no 
prospective study has addressed the association between 
changes in serum 25(OH)D concentrations and changes 
in depressive symptoms over time. Within two cohorts 
of the Longitudinal Aging Study Amsterdam (LASA), 
repeated measurements of serum 25(OH)D and depressive 
symptoms provided the opportunity to prospectively 
study whether changes in serum 25(OH)D over time are 
associated with parallel changes in depressive symptoms 
in Dutch older adults. We hypothesised that an increase 
in 25(OH)D concentration would lead to a decrease in 
severity of depressive symptoms.
Subjects and methods
Study population
LASA is an ongoing Dutch cohort study on the 
determinants, trajectories and consequences of physical, 
cognitive, emotional and social functioning in relation 
to ageing. Participants were recruited from three 
geographic regions in the Netherlands, constituting 
a nationally representative sample of the Dutch older 
population. Measurement cycles are carried out every 
3  years at the participants’ homes, including a main 
interview, medical interview and questionnaire. The 
Medical Ethics Committee of the VU University Medical 
Center (VUmc) approved the study, and all participants 
gave informed consent. A detailed description of the 
sampling and data collection procedures can be found 
elsewhere (34, 35).
Participants
For the present study, data from two LASA cohorts were 
used. At LASA’s start in 1992/1993, 3107 subjects aged 
55–85  years were enrolled in the first cohort (‘older 
cohort’). At the second measurement cycle (1995/1996, 
‘baseline’ of this cohort), persons aged ≥65  years who 
participated in the medical interview (n = 1509) were 
asked to donate a blood sample. Serum 25(OH)D 
concentration was measured in 1320 persons. Serum 
25(OH)D was again measured 13 years later (2008/2009, 
n = 390). For this study, persons with 25(OH)D 
measurements at both cycles were selected (n = 175). 
Two persons were excluded because of missing data on 
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baseline covariates, resulting in an analytical sample of 
173 persons. The recruitment and exclusion of persons 
from the older cohort are shown in Fig. 1A; attrition was 
mainly due to mortality (63.0%) (34).
In 2002/2003, a second LASA cohort was recruited 
consisting of 1002 persons aged 55–65 years (‘younger 
cohort’). The medical interview was completed by 
919 persons. Serum 25(OH)D concentration was 
measured in 2002/2003 (baseline, n = 739) and 6  years 
later (2008/2009, n = 525). A total of 458 persons had 
25(OH)D measurements at both cycles, of which eight 
were excluded due to missing data on the Center for 
Epidemiologic Studies Depression scale (CES-D) at 
follow-up (n = 1) or on baseline covariates (n = 7). The 
recruitment and exclusion of persons from the younger 
cohort are shown in Fig. 1B.
Depression measurements
At all measurement cycles, depressive symptoms were 
assessed by the CES-D, a 20-item self-report scale about 
depressive symptoms experienced in the previous week 
(36). The CES-D has been widely used in older population-
based samples and is a valid and reliable instrument for 
Dutch older adults (37). Total scores range from 0 to 60, 
with a higher score indicating more depressive symptoms. 
Change in depressive symptoms over 13 or 6 years was 
calculated by subtracting the CES-D score at baseline from 
the score at the follow-up cycle.
25(OH)D measurements
Morning blood samples were drawn in 1995/1996 (older 
cohort) and 2002/2003 (younger cohort). Participants 
Figure 1
Flowcharts of the older cohort (A) and the younger cohort (B). 25(OH)D, 25-hydroxyvitamin D; CES-D, Center for Epidemiologic 
Studies Depression scale.
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were allowed to have tea and toast for breakfast, but no 
dairy products. In 2009 (both cohorts), fasting blood 
samples were drawn: participants were not allowed 
to take any food or drink from midnight. All samples 
were centrifuged and stored at −20°C until 25(OH)D 
determination in 1997/1998 (1995/1996 samples) and in 
2010/2011 (2002/2003 and 2009 samples). A competitive 
protein-binding assay was used in 1997/1998 (Nichols 
Diagnostics Capistrano, CA, USA; interassay coefficient of 
variation (CV): 10%), whereas a radioimmunoassay was 
used in 2010/2011 (Diasorin, Stillwater, Minnesota, USA; 
interassay CV: 10%). All measurements were carried out at 
the Endocrine Laboratory of the VUmc.
Before change in 25(OH)D concentration could be 
calculated, the 25(OH)D measurements needed to be 
(1) standardised for assay and (2) corrected for season. 
First, as part of the 7th Framework Programme project 
ODIN, all serum 25(OH)D data have been standardised 
by applying the Vitamin D Standardisation Program 
protocols (38, 39). Without differences in assay, 25(OH)D 
change can be properly calculated (30). Second, individual 
concentrations were deseasonalised before calculating the 
intra-individual change, as blood samples were drawn 
throughout the year and 25(OH)D concentrations vary 
across seasons (highest in summer and autumn, lowest in 
winter and spring) due to changes in ultraviolet radiation 
exposure (32, 40). For this, a sinusoidal regression model 
was fitted:











T / . )365 25
where original 25(OH)D concentration denotes the 
standardised 25(OH)D concentration, T denotes the 
day of the year of blood draw and βj (j = 0, 1, 2) are 
estimated regression coefficients. To obtain individual 
deseasonalised 25(OH)D concentrations, the residuals 
(difference between the predicted value and the original 
value) from this model were added to the annual 
mean of the model (the intercept: β0) (41, 42). In this 
way, the seasonal variation of 25(OH)D concentration 
was adjusted for. Deseasonalising was performed 
separately for each cohort and each measurement 
cycle: for 1995/1996 and 2009 for the older cohort 
and for 2002/2003 and 2009 for the younger cohort. 
Subsequently, intra-individual change in 25(OH)D 
concentration was calculated by subtracting the 
standardised, deseasonalised 25(OH)D concentration 
at baseline from the standardised, deseasonalised 
25(OH)D concentration at follow-up (13 or 6 years later). 
Unless otherwise specified, standardised, deseasonalised 
25(OH)D data were used and reported in this study.
Other variables
Potential confounders were examined at baseline and 
included sex, age, education level, BMI, smoking status, 
alcohol use, physical activity and number of chronic 
diseases. Data on sex and age were derived from municipal 
registries. Participants were asked about their highest 
completed level of education, and this was converted into 
education years. BMI was calculated as measured body 
weight (in kg) divided by squared measured body height 
(in m). Self-reported smoking status was categorised into 
never, former and current smoking. Categories of self-
reported alcohol use were no, light, moderate and (very) 
excessive (43). Physical activity during the past 2 weeks 
(walking outdoors, cycling, sports and heavy household 
activities, in min/day) was assessed using the validated 
LASA Physical Activity Questionnaire (44). Self-reported 
number of chronic diseases included seven major somatic 
diseases: asthma/chronic obstructive pulmonary disease, 
cardiac disease, peripheral arterial disease, diabetes 
mellitus, cerebrovascular accident/stroke, osteoarthritis/
rheumatoid arthritis and cancer. Use of antidepressants 
(yes/no, only used in sensitivity analyses) was retrieved 
during the medical interview using ATC codes of the 
medications that were used at that time by the participant.
Statistical analyses
As age range and follow-up time between the two cycles 
differed between the two cohorts, all analyses were 
conducted separately for each cohort. Absolute change 
in 25(OH)D concentrations was calculated over 13 years 
(older cohort) and over 6 years (younger cohort). Absolute 
change in CES-D score was also calculated over these time 
periods and checked for normality. Paired-samples t-tests 
were performed to assess whether changes over time in 
25(OH)D and CES-D were statistically significant. Serum 
25(OH)D change was used as continuous determinant, 
expressed per 10 nmol/L. To compare participants with 
relatively large 25(OH)D decreases with those with large 
increases, it was also divided in tertiles with tertile 3 
(increase in 25(OH)D concentration) serving as reference 
category. For the continuous baseline characteristics, linear 
regression analyses were used to examine linear trends 
across the tertiles of 25(OH)D change. For the categorical 
variables, chi-square (linear-by-linear association) tests 
were performed to test for trend.
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The associations between change in 25(OH)D and 
change in depressive symptoms over 13 or 6 years were 
analysed by multivariable linear regression analysis. Based 
on previous studies on 25(OH)D and depression (11, 14, 
15, 24), sex was examined as a potential effect modifier. 
Another potential effect modifier was baseline serum 
25(OH)D concentration, as this may influence the change 
in serum 25(OH)D (45). Effect modification was tested by 
including sex or baseline serum 25(OH)D (dichotomous, 
median-split) and the interaction term of the potential 
effect modifier with 25(OH)D change in the unadjusted 
regression models. A P value <0.10 of the interaction 
term(s) was considered statistically significant. Three 
models were made: model 1 was adjusted for baseline 
serum 25(OH)D (to interpret the regression coefficient 
for subjects with the same 25(OH)D concentration at 
baseline); model 2 was additionally adjusted for age, 
sex and education level; and model 3 was additionally 
adjusted for the lifestyle factors BMI, physical activity, 
alcohol use and smoking. To test linear trends across 
the tertiles, the categorical tertile variable was used as a 
continuous variable to retrieve a P value for trend.
Three sensitivity analyses were conducted. First, 
all analyses were additionally adjusted for number of 
chronic diseases in a separate model, as this covariate 
might confound and/or mediate the association causing 
potential overadjustment. Second, in order to check 
whether changes in lifestyle factors affect the association, 
model 3 was additionally adjusted for the changes in 
BMI, physical activity (both absolute continuous change), 
alcohol use and smoking (both categorical: stable, 
increase, decrease). Third, all analyses were repeated 
after exclusion of participants who used antidepressants 
at baseline or at one or more of the measurement cycles 
during the follow-up period.
All analyses were performed using SPSS version 23 




Participants from the older cohort (n = 173) had a median 
age of 68.9  years (interquartile range (IQR): 67.0–72.3) 
and the mean baseline deseasonalised serum 25(OH)D 
was 58.2 nmol/L (standard deviation (s.d.): 16.1) (Table 1). 
The median age of participants from the younger cohort 
(n = 450) was 59.8 years (IQR: 57.0–62.2) and their mean 
baseline deseasonalised serum 25(OH)D was 59.5 nmol/L 
(s.d.: 17.9). When comparing the 25(OH)D change tertiles 
from the older cohort, participants from tertile 1 tended 
to be more educated and tended to drink more alcohol 
compared to the other tertiles. In the younger cohort, 
participants from tertile 1 were more often women and 
tended to have more chronic diseases.
Comparison of included (n = 173) and excluded 
(n = 1336, Fig.  1A) participants from the older cohort 
showed that excluded participants had lower 25(OH)D 
concentrations (P < 0.001), more depressive symptoms 
(P < 0.001), were older (P < 0.001), less physically active 
(P < 0.001), more often smokers (P = 0.002), drank less 
alcohol (P < 0.001) and had more chronic diseases 
(P < 0.001). In the younger cohort, this comparison 
showed that excluded participants (n = 469, Fig.  1B) 
had more depressive symptoms (P = 0.044), were more 
often smokers (P = 0.004) and had more chronic diseases 
(P = 0.019) compared to included participants (n = 450).
Absolute change in serum 25(OH)D concentrations 
and depressive symptoms
Figure  2 shows the absolute, intra-individual change in 
serum 25(OH)D over 13  years for the older cohort and 
over 6  years for the younger cohort. The difference in 
distribution between the two cohorts becomes clear from 
the cutoff values of the tertiles. In the older cohort, 117 
participants (67.6%) experienced a decrease in 25(OH)D  
concentration, whereas this was 172 (38.2%) in the 
younger cohort. Mean 25(OH)D of participants from the 
older cohort decreased by 6.9 nmol/L (s.d.: 20.9, P < 0.001). 
The mean CES-D score increased during the same time 
period by 2.0 points (s.d.: 6.5, P < 0.001), suggesting 
increasing depressive symptoms over time. In the younger 
cohort, mean 25(OH)D increased by 5.5 nmol/L (s.d.: 
17.8, P < 0.001), and the mean CES-D score decreased 
by 0.7 points (s.d.: 6.5) over 6 years (P < 0.027). Change 
in depressive symptoms was normally distributed in 
both cohorts.
Association between change in serum 25(OH)D and 
change in depressive symptoms
In the older cohort, change in serum 25(OH)D (as 
continuous determinant) was not associated with change 
in CES-D score after adjustment for baseline 25(OH)D 
concentration. Similarly, tertiles of 25(OH)D change did 
not show an association, and the P for trend was not 
statistically significant (0.246). No interactions with sex 
and baseline 25(OH)D were observed.
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In the younger cohort, significant interactions 
between change in 25(OH)D and both baseline 25(OH)D 
(P = 0.042) and sex (P = 0.087) were observed. After 
stratification for baseline 25(OH)D, sex was no longer an 
effect modifier (P = 0.139 and 0.453). Participants below 
the median of 58.6 nmol/L showed a negative association 
(B per 10 nmol/L increase, model 3: −0.62 (95% CI: −1.17, 
−0.07)), meaning that a more positive 25(OH)D change 
(indicating less decrease or even an increase in 25(OH)D) 
was associated with a decrease in CES-D score (indicating 
a reduction in depressive symptoms). A similar association 
was observed for the 25(OH)D change tertiles (B tertile 
1 vs tertile 3, model 3: 3.07 (95% CI: 0.73, 5.40)). In 
participants with baseline 25(OH)D above the median, no 
associations were found (Table 2).
Sensitivity analyses
Additional adjustment for number of chronic diseases 
did not markedly change the findings in both cohorts. 
Similarly, additional adjustment for changes in four 
lifestyle factors did not change the findings. Furthermore, 
findings from the older cohort were similar when 
participants who used antidepressants at baseline (n = 4) 
or during follow-up (n = 17) were excluded. In the younger 
cohort, exclusion of baseline antidepressant users 
(n = 17) or follow-up users (n = 26) resulted in somewhat 
stronger associations in those with a baseline 25(OH)D 
concentration below 58.6 nmol/L (e.g. in n = 424: B, tertile 
1 vs tertile 3, model 3: 3.30 (95% CI: 0.96, 5.63)).
Discussion
In this study, we observed no associations between 
change in serum 25(OH)D concentration and parallel 
change in depressive symptoms in a cohort of older adults 
(65–88 years at baseline, follow-up 13 years). Neither did 
we find associations in a younger cohort (55–65  years 
at baseline, follow-up 6 years) with a baseline 25(OH)D 
concentration above 59 nmol/L. However, in participants 
from the younger cohort with a lower baseline 25(OH)D, 
we observed that an increase in 25(OH)D concentration 
was associated with a decrease in severity of depressive 
symptoms.
The observed associations between change in 25(OH)D 
concentration and change in depressive symptoms 
differed between the two cohorts. In the younger cohort, 
a 10 nmol/L increase in serum 25(OH)D was associated 
with a 0.62 points lower CES-D score, but only if baseline 
25(OH)D concentrations were relatively low. The null 
findings in the younger cohort’s group with relatively 
Figure 2
Histograms of change in deseasonalised serum 
25-hydroxyvitamin D over 13 years in the older cohort (A) and 
over 6 years in the younger cohort (B). Dashed lines indicate 
the cutoff values of the tertiles. The mean ± s.d. changes in 
25-hydroxyvitamin D were for tertile 1: −27.1 ± 12.0, tertile 2: 
−9.3 ± 4.2 and tertile 3: 16.2 ± 14.3.
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high baseline 25(OH)D concentrations suggest that a 
change in 25(OH)D concentration above a certain level – 
we used the median of 59 nmol/L – has less influence on 
depressive symptoms. However, this was not confirmed in 
the older cohort. An explanation for the non-significant 
association in the older cohort may be the small sample 
size (n = 173), which limited the statistical power. The 
betas of the older cohort were in the same direction and 
of comparable size as those in the younger cohort’s group 
with relatively low baseline 25(OH)D concentrations.
To the best of our knowledge, this is the first 
observational study that investigated intra-individual 
change in 25(OH)D in relation to intra-individual 
change in depressive symptoms. Our results suggest 
that supplementation of vitamin D in those with 
relatively low baseline levels might positively influence 
depressive symptoms. Indeed, a 12-month vitamin D 
supplementation trial in overweight adults showed that 
25(OH)D concentrations increased from 55 to 112 nmol/L 
in the group receiving 40 000 IU vitamin D3 per week and 
from 52 to 88 nmol/L in the group receiving 20 000 IU per 
week, compared to no change (from 52 to 50 nmol/L) in 
the placebo group; the treatment groups had a significant 
greater reduction in depressive symptoms than the 
placebo group (25). However, other RCTs, which reported 
pre- and post-intervention 25(OH)D concentrations, 
showed a larger 25(OH)D increase in the treatment group 
but no effect on depression (26, 46) or mental well-being 
(47, 48). Thus, more research is needed to further elucidate 
the potential impact of 25(OH)D change on depressive 
symptoms.
In our previous prospective study, an inverse 
association between baseline 25(OH)D and depressive 
symptoms over 6 years was found only in women from 
the older LASA cohort (24). In the present study, with 
change in 25(OH)D as determinant instead of baseline 
25(OH)D, sex was not an effect modifier in the older 
cohort. Explanations for this might be differences in the 
study sample and the limited power (n = 173 vs 1282). 
In addition, De Koning, et al. (24) found no association 
in the younger cohort, whereas we did for those with 
low baseline 25(OH)D. This discrepancy might be 
explained by general health status: being healthy might 
be important to withstand negative effects on mood of 
a low 25(OH)D, but not negative effects of a decrease 
in 25(OH)D.
Table 2 Associations between change in deseasonalised serum 25(OH)D and change in CES-D score.
n
Model 1 Model 2 Model 3
β 95% CI β 95% CI β 95% CI
Older cohort, 13 years follow-up (n = 173)
 Change in 25(OH)D† −0.27 (−0.79, 0.26) −0.22 (−0.76, 0.31) −0.16 (−0.70, 0.37)
 Change in 25(OH)D in tertilesa
  Tertile 1 58 2.21 (−0.36, 4.79) 1.95 (−0.66, 4.57) 1.63 (−0.98, 4.24)
  Tertile 2 58 0.05 (−2.34, 2.44) −0.02 (−2.42, 2.38) −0.28 (−2.68, 2.11)
  Tertile 3 57 Reference Reference Reference
  P for trend 0.103 0.162 0.246
Younger cohort, 6 years follow-up: Baseline deseasonalised 25(OH)D <58.6 nmol/L (n = 225)
 Change in 25(OH)D† −0.63 (−1.16, −0.09)* −0.64 (−1.18, −0.09)* −0.62 (−1.17, −0.07)*
 Change in 25(OH)D in tertilesb
  Tertile 1 51 3.28 (1.00, 5.56)** 3.30 (0.98, 5.62)** 3.07 (0.73, 5.40)*
  Tertile 2 82 1.51 (−0.48, 3.50) 1.48 (−0.52, 3.49) 1.67 (−0.35, 3.69)
  Tertile 3 92 Reference Reference Reference
  P for trend 0.005 0.005 0.008
Younger cohort, 6 years follow-up: Baseline deseasonalised 25(OH)D >58.6 nmol/L (n = 225)
 Change in 25(OH)D† 0.21 (−0.27, 0.68) 0.23 (−0.25, 0.71) 0.27 (−0.22, 0.76)
 Change in 25(OH)D in tertilesb
  Tertile 1 99 −0.80 (−2.90, 1.30) −0.91 (−3.04, 1.23) −0.85 (−3.00, 1.30)
  Tertile 2 68 −1.00 (−3.22, 1.22) −1.12 (−3.35, 1.11) −0.92 (−3.16, 1.31)
  Tertile 3 58 Reference Reference Reference
  P for trend 0.501 0.451 0.470
Model 1: adjusted for baseline standardised and deseasonalised 25(OH)D concentration. Model 2: additionally adjusted for age, sex and education level. 
Model 3: additionally adjusted for BMI, physical activity, alcohol use and smoking.
aTertiles older cohort: T1 −78.6 to −16.4, T2 −16.3 to −0.7, T3 −0.6 to 66.2 nmol/L. bTertiles younger cohort: T1 −54.0 to −2.7 (n = 150), T2 −2.7 to 11.8 
(n = 150), T3 11.9 to 81.3 (n = 150) nmol/L.
*P-value <0.05, **P-value <0.01; †Change in 25(OH)D (continuous, per 10 nmol/L).
CES-D, Center for Epidemiologic Studies Depression scale; CI, confidence interval; β, unstandardised regression coefficient.
Downloaded from Bioscientifica.com at 11/07/2020 12:37:24PM






















179:4 247Clinical Study L E M Elstgeest and others Change in 25OHD and 
depressive symptoms
www.eje-online.org
In the present study, we also observed a difference 
between the two cohorts with respect to the distributions 
of 25(OH)D changes: 62% of the younger cohort had an 
increase in serum 25(OH)D concentration over 6  years, 
compared to 32% of the older cohort over 13 years. This 
difference might be explained by age differences (55–
65 years in the younger cohort at baseline vs 65–88 years 
in the older cohort). Older persons may have reduced 
their outdoor activities with ageing due to for example 
functional limitations, leading to less exposure to 
sunlight (9, 49). Our results are similar to those of the 
Tromsø Study, in which subjects older than 65  years at 
baseline had a decrease in serum 25(OH)D of 0.3 nmol/L 
over 14 years, while those younger than 65 years had an 
increase of 2.0 nmol/L (P < 0.05) (50). Furthermore, our 
mean 13-year change in 25(OH)D in the older cohort 
(−6.9 nmol/L) and 6-year change in the younger cohort 
(+5.5 nmol/L) were comparable but slightly different to 
previous findings within LASA that were based on different 
statistical models and on measurements that were not yet 
standardised. Van Schoor et al. (40) showed that 25(OH)D  
concentrations decreased with 6.5 nmol/L in the older 
cohort and increased with 2.4 nmol/L in the younger 
cohort (see their Table 3: age per year (longitudinal)).
Our study has several strengths, including its 
longitudinal design, a nationally representative sample of 
older adults, and the use of deseasonalised serum 25(OH)D  
values at two time points. Further, the measurements of 
25(OH)D were standardised for assay. Limitations of this 
study are the relatively healthy study population – as 
most participants needed to visit the hospital for blood 
sampling – and the exclusion of participants with only 
one serum 25(OH)D measurement that resulted in smaller 
and less representative samples. Moreover, our study was 
limited by the use of self-reported depressive symptoms 
during the past week instead of a clinical assessment; 
however, the CES-D scale has been shown to have good 
psychometric properties in samples of older adults (37). 
Reverse causality is a limitation as well, since we do not 
know when the changes occurred during the 13 or 6 years; 
an increase in depressive symptoms might have occurred 
before the decrease in 25(OH)D. However, our previous 
paper showed that baseline 25(OH)D was associated 
with the onset of depressive symptoms over 6  years in 
older women without depressive symptoms at baseline 
(24). This indicated an association in the direction from 
25(OH)D to depression, which was the assumption for 
the present study. Lastly, no data on supplement use or 
nutritional intake of vitamin D were available. However, 
measured 25(OH)D concentrations are a more valid 
estimate of vitamin D status than intake from foods and 
supplements (33).
In conclusion, our study suggests that a decrease in 
serum 25(OH)D concentration over 6 years is associated 
with a parallel increase in depressive symptoms in 
young older adults with a low baseline 25(OH)D. We 
did not observe an association in young older adults 
with a higher baseline 25(OH)D over 6 years, or in older 
adults over a period of 13 years. Whether specific groups 
may emotionally benefit from an increase in vitamin D 
concentration (e.g. persons with relative low 25(OH)D  
concentrations) needs further investigation; well-
designed RCTs are needed to determine the potential 
causal association between vitamin D and depression.
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